December 2016
-
Retrophin, which is developing Syntocinon intranasal oxytocin, has named Stephen Aselage as President and Chief Operations Officer and Alvin Shih as Executive VP of Research and Development. Aselage, who has stepped down as CEO, was… Read more . . .
-
Arikayce inhaled liposomal amikacin developer Insmed has announced that former AstraZeneca CEO David R. Brennan will join the company’s board of directors. Insmed Chairman of the Board Donald J. Hayden commented, “We are delighted to… Read more . . .
-
According to Trimel Pharmaceuticals, the FDA has approved its Natesto nasal testosterone for men with low levels of endogenous testosterone. Trimel submitted an NDA for the product, then called CompleoTRT, in April 2013. Trimel President… Read more . . .
-
Trimel Pharmaceuticals has announced that an 84-day Phase 2 trial of its Tefina testosterone nasal gel for the treatment of anorgasmia in women found that the lowest of three doses tested produced a statistically significant… Read more . . .
-
A six-month study conducted by the Woolcock Institute of Medical Research (WIMR) found that patients getting reminders from the Smartinhaler SmartTrack inhaler monitoring system manufactured by Nexus6 took 73% of prescribed doses on average compared… Read more . . .
-
The FDA has approved Teva’s QVAR beclomethasone HFA metered dose inhaler with a dose counter for the treatment of asthma, and the company plans to launch the product later in 2014, Teva said. Teva Global… Read more . . .
-
Boston-based AZTherapies says that it plans to initiate a Phase 3 study of its ALZT-OP1, an inhaled combination product for the prevention and treatment of Alzheimer’s disease, by the end of 2014 now that it… Read more . . .
-
GlaxoSmithKline has submitted an NDA for its umeclidinium (UMEC) Ellipta DPI for the treatment of COPD to the Japanese Ministry of Health, Labour and Welfare, the company announced. The product was approved under the name… Read more . . .
-
Boehringer Ingelheim has presented data from a 6-week Phase 3 study of its tiotropium/olodaterol soft mist inhaler in 219 moderate to severe COPD patients showing that patients using the fixed dose combination had significantly greater… Read more . . .
-
According to Swedish CRO Medicon Valley Inhalation Consortium (MVIC), the organization has entered into a 2-year, €1.6 million contract with a Chinese company to develop an inhaled generic drug for the treatment of asthma and… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland